title: Survival analysis of adjuvant chemotherapy with S-1 plus cisplatin for stage III gastric cancer.
abstract: BACKGROUND
  We previously reported that S-1 plus cisplatin was feasible as adjuvant chemotherapy for stage III gastric cancer after D2 gastrectomy. Herein we evaluate the recurrence-free survival and overall survival rates as secondary endpoints based on updated follow-up data.
  
  
  METHODS
  Patients with stage III gastric cancer who underwent D2 gastrectomy were enrolled. Treatment consisted of 3 cycles of S-1 (40 mg/m(2) PO) twice daily on days 1-21 and cisplatin (60 mg/m(2) IV) on day 8, and S-1 was given on days 1-28 every 6 weeks until 1 year after surgery.
  
  
  RESULTS
  From August 2007 to September 2009, 63 patients were accrued. Overall, 34 and 25 patients had stage IIIA and IIIB disease, respectively. After a median follow-up of 3.9 years, 16 patients experienced recurrence and 11 patients died. The 3-year recurrence-free survival rate was 74.1 % (95 % CI: 60.8-83.5 %, IIIA 81.8 %, IIIB 64.0 %). The 3-year overall survival rate was 84.5 % (95 % CI: 72.3-91.6 %, IIIA 87.9 %, IIIB 80.0 %). Recurrence sites included the peritoneum (n = 8), hematogenous sites (n = 6), and lymph nodes (n = 4).
  
  
  CONCLUSIONS
  The present results indicate that adjuvant therapy with S-1 plus 3 cycles of cisplatin may provide a survival benefit to patients with stage III gastric cancer.
authors.affiliation: Department of Clinical Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, 464-8681, Aichi, Japan, dtakahari@aichi-cc.jp.
authors.forename: Daisuke
authors.initials: D
authors.lastname: Takahari
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Hamaguchi
authors.forename: Kenichi
authors.initials: K
authors.lastname: Yoshimura
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Katai
authors.forename: Seiji
authors.initials: S
authors.lastname: Ito
authors.forename: Nozomu
authors.initials: N
authors.lastname: Fuse
authors.forename: Masaru
authors.initials: M
authors.lastname: Konishi
authors.forename: Hirofumi
authors.initials: H
authors.lastname: Yasui
authors.forename: Masanori
authors.initials: M
authors.lastname: Terashima
authors.forename: Masahiro
authors.initials: M
authors.lastname: Goto
authors.forename: Nobuhiko
authors.initials: N
authors.lastname: Tanigawa
authors.forename: Kuniaki
authors.initials: K
authors.lastname: Shirao
authors.forename: Takeshi
authors.initials: T
authors.lastname: Sano
authors.forename: Mitsuru
authors.initials: M
authors.lastname: Sasako
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D004338:Drug Combinations; D005500:Follow-Up Studies; D006801:Humans; D008207:Lymphatic Metastasis; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology; D009367:Neoplasm Staging; D010094:Oxonic Acid / Q000008:administration & dosage; D010534:Peritoneal Neoplasms / Q000188:drug therapy / Q000401:mortality* / Q000556:secondary; D011379:Prognosis; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology; D015996:Survival Rate; D005641:Tegafur / Q000008:administration & dosage
chemical_list: D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D002945:Cisplatin